Business Context and Reporting Period
Whitehawk Therapeutics, Inc. (WHWK) is a clinical-stage oncology therapeutics company focused on developing next-generation antibody drug conjugates (ADCs). The company divested its legacy commercial product, FYARRO, in March 2025. This Form 10-Q covers the quarterly period ended June 30, 2026, and the six months ended June 30, 2026. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $0 | $7,145 |
| Net Loss | $(38,834) | $20,401 (Net Income) |
| Operating Expenses | $41,631 | $77,112 |
| Research & Development | $30,125 | $57,597 |
| Selling, General & Administrative | $11,506 | $18,755 |
| Cash and Cash Equivalents (End of Period) | $85,234 | $144,936 |
| Short-term Investments (End of Period) | $104,748 | $108,129 |
| Total Liquidity (Cash + Investments) | $189,982 | $253,065 |
| Accumulated Deficit | $(392,084) | $(353,250) |
Material Changes vs. Prior Period
- Revenue Elimination: The company reported zero revenue for the six months ended June 30, 2026, compared to $7.1 million in the prior year period. This is due to the divestiture of the FYARRO business on March 25, 2025.
- Net Loss vs. Net Income: The company incurred a net loss of $38.8 million in the current period, contrasting with net income of $20.4 million in the prior period. The prior year income was primarily driven by an $87.4 million gain on the sale of the FYARRO business.
- Expense Reduction: Total operating expenses decreased by approximately $35.5 million year-over-year. Research and development expenses dropped significantly ($27.5 million decrease) largely because the prior period included a $38.0 million upfront license fee paid to WuXi Biologics. SG&A expenses decreased by $7.3 million due to the divestiture of commercial operations.
- Capital Raise: In May 2026, the company completed a PIPE financing, raising net proceeds of $81.8 million through the sale of common stock and pre-funded warrants.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments of approximately $190 million will fund operations into the second half of 2028.
- Pipeline Progress: The company is advancing three ADC Therapies (HWK-007, HWK-016, and HWK-206). Phase 1 trials for HWK-007 and HWK-016 are actively recruiting, with data readouts expected in the first half of 2027. An IND for HWK-206 is expected to be cleared by mid-2026.
- Strategic Expansion: In May 2026, the company entered an option agreement with Hangzhou DAC for up to five additional ADC programs and a collaboration with Biocytogen for bispecific ADCs.
- Key Risks:
- Regulatory Approval: No products are currently approved; success depends on clinical trial outcomes and FDA approval.
- China Exposure: The company relies on WuXi Biologics and Hangzhou DAC (China-based) for manufacturing and technology. The BIOSECURE Act and U.S.-China trade tensions pose potential supply chain and regulatory risks.
- Capital Requirements: The company expects to continue incurring significant losses and will require additional financing to complete development and commercialization.
Investor Verification Checklist
- Verify the status and enrollment rates of the Phase 1 clinical trials for HWK-007 and HWK-016.
- Confirm the terms and potential dilution impact of the outstanding pre-funded warrants (approx. 36.9 million shares total from 2022, 2024, and 2026 financings).
- Assess the specific risks associated with the BIOSECURE Act regarding the company's reliance on Chinese partners (WuXi Biologics and Hangzhou DAC).
- Review the burn rate and cash runway projections to ensure the $190 million liquidity position is sufficient to reach the anticipated 2028 milestone.
- Monitor the progress of the new option agreement with Hangzhou DAC and the collaboration with Biocytogen for pipeline expansion.